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INTERNATIONAL JOURNAL OF CLINICAL PHARMACY 1 
Lorna West, Maria Cordina, Lesley Diack, Derek Stewart 2 
A focus group based study of the perspectives of the Maltese population and healthcare 3 
professionals on medication wastage  4 
 5 
Background 6 
According to the World Health Organization (WHO) global estimates published in 2004, 7 
more than half of all medication is prescribed, dispensed or sold inappropriately with a 8 
resultant “wastage of scarce resources and widespread health hazards”.1 Medication 9 
wastage continues to be of paramount importance to public health in terms of safety, the 10 
environment and the economy. A systematic review of the literature identified 42 published 11 
papers, all employing a quantitative cross-sectional design. The main factors contributing to 12 
wastage were ‘change in medication’, ‘patient's death’, ‘resolution of patient's condition’ and 13 
‘medication passed expiry date’. There was a clear absence of qualitative research exploring 14 
wastage from the perspectives of key stakeholders (members of the public, patients, 15 
healthcare professionals [HCPs] and policy makers), with no studies founded on behavioural 16 
theories.2 17 
 18 
There is an urgent need to develop, implement and sustain wastage reduction strategies. Such 19 
interventions are likely to be complex, defined by the United Kingdom Medical Research 20 
Council (MRC) as “interventions with several interacting components”.3 The MRC 21 
highlights several stages for development and evaluation of complex interventions, 22 
emphasising the need for a good theoretical understanding of how an intervention could bring 23 
about change. Developing processes which include behaviour change theories impacts 24 
significantly the positive implementation of evidence into healthcare practice.  25 
 26 
Aim  27 
The aims of this research were to describe and understand the beliefs and behaviours 28 
regarding medication wastage of the Maltese public and HCPs and to explore potential 29 
solutions. 30 
 31 
Ethical approval 32 
The study was approved by the School of Pharmacy and Life Sciences Research Ethics 33 
Committee, Robert Gordon University and the University of Malta Research Ethics 34 
Committee. 35 
 36 
Method 37 
Design 38 
This was an interpretative study based on a theoretical basis using focus groups of 39 
participants.  40 
 41 
Setting 42 
This study was conducted in Malta, an island in the middle of the Mediterranean sea with a 43 
population of 416,110.4 The healthcare system in Malta is based mainly on taxation with a 44 
centrally organized health service provided mainly by public health providers.5 Medication in 45 
Malta is either purchased by the patient or supplied to the patient free of charge by the 46 
government, based on entitlement criteria. 47 
 48 
Inclusion criteria, sampling and sample size 49 
As part of a related study 1,920 randomly selected members of the general public and 1,680 50 
HCPs (all dentists, doctors and pharmacists) were invited to complete a questionnaire on 51 
medication wastage.6 As part of this mailing, they were invited to participate in a focus group 52 
study. Those interested were requested to complete and return an ‘expression of interest 53 
form’ indicating the most preferred time of the day to attend. Only the data from the focus 54 
groups is included in this manuscript. 55 
 56 
Five focus groups each containing six participants were planned, three with HCPs and two 57 
for the general public. Purposive sampling was used to select participants of different ages, 58 
gender and education levels (public); and HCP professions.  59 
 60 
Topic guide development 61 
The topic guide was based on the key findings from the questionnaire study6 and the 14 62 
domains of the Theoretical Domains Framework (TDF). The topic guides for HCPs and 63 
general public were similar; the public one also translated into Maltese. The use of a 64 
theoretical basis, the TDF and associated domains were used to aid the construction of the 65 
topic guide and coding framework, to ensure that the research and outputs were grounded in a 66 
behavioural theory which focuses on change. 67 
 68 
TDF The TDF was developed by psychological theorists, health psychologists and 69 
researchers  to simplify and integrate 33 theories and 128 into a 12 stage TDF (now extended 70 
to 14) of: knowledge; skills; social/professional role and identity; beliefs about capabilities; 71 
optimism; beliefs about consequences; reinforcement; intentions; goals; memory, attention 72 
and decision processes; environmental context and resources; social influences; emotion; 73 
behavioural regulation.7 TDF has been used in several studies to explain implementation 74 
problems and inform implementation interventions.8,9,10 75 
 76 
Focus group process 77 
The focus groups were of approximately 90 minutes duration, were conducted by the 78 
principal researcher in a conference room of a centrally located hotel, audiorecorded and 79 
transcribed verbatim, with Maltese statements translated into English.  80 
 81 
Main outcome measures 82 
Beliefs and behaviours regarding medication wastage and potential solutions to reduce 83 
medication wastage. 84 
 85 
Data analysis 86 
Analysis was carried out using the framework approach,11 with the coding frame developed 87 
and applied independently by two researchers to promote confirmability, and mapped to TDF 88 
domains.  89 
 90 
Results 91 
Participant demographics 92 
Tables 1 and 2 provide a description of the participants’ demographics. 93 
Insert Table 1 here. 94 
Insert Table 2 here. 95 
 96 
Key themes identified within TDF domains  97 
Key themes emerged from the focus groups, namely: practitioner effects, patient effects, 98 
political effects and societal effects. An overlap of these four key themes was noticed when 99 
mapped to the different TDF domains listed in the first column of Table 3. A wide range of 100 
sub-themes emerged from these four key themes, with several of these sub-themes mapped to 101 
one domain also aligned to other TDF domains, such as the healthcare system and medication 102 
unavailability emerging under different domains. 103 
  104 
Insert Table 3 here. 105 
 106 
Behavioral regulation was the TDF domain which emerged most strongly with both HCPs 107 
and members of the public. Implementation of solutions to minimise medication wastage 108 
requires behavioural change. In terms of potential solutions to reduce wastage, these were 109 
described under the domain of behavioural regulation in terms of facilitators to alter 110 
behaviour; therefore the findings of the domain ‘Behavioural regulation’ will be presented 111 
below. 112 
 113 
Domain: Behavioural regulation 114 
1. Practitioner effects 115 
Several noted the need to engender a culture of accountability in HCPs,  116 
 117 
"... so if we are going to invest in an IT system and we are not going to make anybody 118 
accountable for the cost, we are just going to spend money on an IT system". 119 
(Female, hospital pharmacist, part-time community pharmacist, 9 years in practice) 120 
 121 
Medication use reviews (MURs) were discussed as a potential for HCPs and patients to 122 
optimise medication and reduce wastage, 123 
 124 
"In the UK patients are even reviewed by the pharmacist, the MURs. And that has reduced a 125 
great deal of costs for the NHS. Reviews are then every year for example". 126 
(Male, hospital pharmacist, part-time-community pharmacist, 12 years in profession) 127 
 128 
A standardised patient review template was suggested, which would be mandatory and 129 
updated regularly following patient assessment prior to prescribing, 130 
 131 
"…together with the prescription, every 6 months they have to show something given to the, 132 
by the doctor, of what the examination found. Maybe the blood pressure, the treatment they 133 
are on. Maybe every 6 months something is filled in as proof that the patient was examined". 134 
(Female, hospital doctor, 4 years in profession) 135 
 136 
The nurse within the public focus group discussed prescribing guidelines, 137 
 138 
"More guidelines... if for example a patient is on certain medication, you can prescribe for 139 
certain amount, for certain time". 140 
(Male, Nurse, 34 years, post-graduate qualifications) 141 
 142 
while others stressed the need for better communication between the private and public health 143 
sector and at all levels of the medication supply chain, 144 
 145 
"From the manufacturer, to the agent, to the wholesaler, to the pharmacy and eventually to 146 
the patient. And between the pharmacy and the patient there is the doctor prescribing. Now if 147 
there is more communication between each level, maybe on consumptions, prescribing 148 
trends, etc., I think that wastage could be reduced at each level". 149 
(Male, hospital pharmacist, part-time-community pharmacist, 12 years in profession) 150 
 151 
2. Patient  effects 152 
Participants described the patients’ fear of unavailability of medication as a major obstacle to 153 
their desire to reduce wastage, and thus the need for reassurance of medication availability. In 154 
fact one of the pharmacists pointed out that patients explicity expressed concerns, 155 
 156 
"We see it, I mean quite frequently, people you know, they just tell us outright ‘cause I don’t 157 
really need this medication, I have at home you know. But will it be available the next time I 158 
collect my medicines?’...".  159 
(Male, hospital pharmacist, 12 years in profession) 160 
 161 
A hospital pharmacist suggested that patient groups and organisations could support, 162 
encourage and reassure patients around appropriate medication ordering and use, 163 
 164 
"And the coeliac association had created a system.... they had like a support group, they 165 
could meet or there was a liaising person and you know that you could go there and maybe 166 
they could spare you a packet of gluten free flour. And I used to feel that that system was a bit 167 
of like a reassurance to those patients". 168 
(Female, hospital pharmacist, part-time-community pharmacist, 13 years in profession) 169 
 170 
Patient empowerment, specifically the need to empower patients to improve non-adherence 171 
was also discussed. Non-adherence leading to wastage was attributed to issues such as poor 172 
education and adverse effects, 173 
  174 
"Yes because their education is low, so they won’t take their medication properly". 175 
(Female, hospital pharmacist, 24 years in profession) 176 
 177 
"...I think patients get side effects from medicines and they decide to stop them because of 178 
side effects in the initial period". 179 
(Female, hospital pharmacist, 24 years in profession) 180 
 181 
3. Political effects 182 
The need to reduce political interference in the organisation and delivery of health services, 183 
assigning strategy and decision making to HCPs, was discussed at length. As a member of the 184 
public commented, 185 
 186 
"… health is a sector that needs to be separated from politics. The administrative side of it is 187 
one thing, the medical side of it is another thing, the regulating is another thing. So I think 188 
the health sector needs to be separate. I don’t know how it can be done; it needs to be 189 
separated from the Government. If we need to get anywhere I mean". 190 
(Female, Assistant Director, 32 years, post-graduate qualifications) 191 
 192 
However, numerous solutions to medication wastage that could be implemented by 193 
politicians and policy makers, particularly in relation to the free healthcare system in Malta, 194 
were discussed. HCPs and the public described the importance of stock management and 195 
forecasting of medication requirements,  196 
 197 
"So we need to have a simple system which is continuously updated by the healthcare 198 
professionals and even GPs who are seeing trends coming, at the general practice and even 199 
at hospital, and this system is being updated by the doctors and even by professionals who 200 
are reading papers about upcoming medicines… ". 201 
(Male, accountant, 24 years, post-graduate qualifications) 202 
 203 
Focusing attention around highly prevalent medical conditions when budgeting was 204 
suggested,  205 
 206 
"We are talking about cardiovascular; it’s a huge chunk of our budget, cardiovascular 207 
medications and diabetes. I think if we are more selective in the medications we use in those 208 
two groups; the cost savings will be quite significant". 209 
(Female, hospital pharmacist, part-time-community pharmacist, 13 years in profession) 210 
 211 
A member of the public suggested the introduction by policy makers of a patient specific 212 
pharmaceutical identity card containing all medication history for both privately purchased 213 
medication and those obtained for free to prevent re-dispensing, 214 
 215 
"I thought if they had an ID card, sort of pharmaceutical ID with… what you’ve been 216 
prescribed, on a chip… so that you can see what they’ve been prescribed previously as well 217 
and even for repeat prescription abuse or over, you know people, over, stock piling. Because 218 
you can see, look, they just came in and had this". 219 
(Female, Director, 36 years, post-graduate qualifications) 220 
 221 
A number discussed the importance of good infrastructure, with one participant adding the 222 
introduction of a centralised patient medication record,  223 
 224 
"One thing I was going to mention is that in the community there should be an IT system 225 
where you, where if I go to a doctor and maybe next month I don’t find my own doctor, and I 226 
have to go to another doctor, then there should be a record". 227 
(Female, hospital pharmacist, part-time-community pharmacist, 5 years in profession) 228 
 229 
Incentives by politicians for HCP to reduce wastage were suggested, 230 
 231 
"If not, there should be steps that are taken where if they don’t want to take that 232 
responsibility, there is no incentive, they need to be incentivised somehow". 233 
(Female, Director, 36 years, post-graduate qualifications) 234 
 235 
A hospital pharmacist mentioned the need to regulate use of high consumption, low cost 236 
medication which could result in a higher total cost compared to low consumption, high cost 237 
medication, 238 
 239 
"When you mention high cost medication, we tend to go see one tablet, how much that costs. 240 
But really when you have high consumption items their cost might actually be higher than the 241 
high cost". 242 
(Male, hospital pharmacist, 12 years in profession) 243 
 244 
The aim of disease prevention with resultant decrease in the need for medication was 245 
discussed. The employment of, for example, more nutritionists in hospitals was suggested,  246 
 247 
"Because this is like a chain, ‘cause if I am eating for my health, I will not get high 248 
cholesterol... Even the Government would save a lot of money". 249 
(Female, housewife, 56 years, secondary level of education) 250 
 251 
4. Societal effects 252 
Making patients, HCPs, politicians and the society as a whole more aware of the cost of 253 
medication, particularly those supplied free to the patient, was highlighted as a positive move 254 
in regulating behaviour,  255 
 256 
"… but I think if we make people aware, especially politicians and doctors, how much it is.  I 257 
think there will be much more awareness, as money, as pills. I don’t know the exact amount 258 
... yes but especially politicians, I think they don’t know the extent so they do not know if it is 259 
a problem...". 260 
(Male, Nurse, 34 years, post-graduate qualifications) 261 
 262 
Several suggested more education on appropriate medication use, starting with the very 263 
young and using different targeting strategies,  264 
 265 
"...for example if you need the youngsters, there is the social media, Facebook, Twitter, 266 
everything, computer...". 267 
(Male, Nurse, 34 years, post-graduate qualifications) 268 
 269 
and settings such as as the workplace,  270 
 271 
"... so why shouldn’t we educate people at the workplace?... You would tell me maybe not all 272 
workers can attend. No, but we should try to do it even in their breaks, get someone who is 273 
competent". 274 
(Female, housewife, 56 years, secondary level of education) 275 
 276 
A medication education campaign amongst patients was also proposed as a measure to 277 
regulate behaviour, 278 
 279 
"Launch a medication education campaign. You have to tell the patient that if they stop 280 
wasting the medication… that money can go somewhere else which can end up helping 281 
them". 282 
(Female, hospital doctor, 17 years in profession) 283 
 284 
Discussion 285 
Key findings  286 
Four key themes (practitioner effects, patient effects, political effects and societal effects) and 287 
a wide range of sub-themes were identified within the TDF domains. Focus groups conducted 288 
with HCPs and the general public identified the following five key themes to address in 289 
proposing solutions to minimise medication wastage under the behavioural regulation 290 
domain: system effects; practitioner effects; patients effects; political effects; awareness and 291 
educational effects. 292 
 293 
Strengths and weaknesses 294 
To our knowledge this is the first interpretative study providing a detailed description of 295 
behaviours around medication wastage, with attention paid to solutions and facilitators of 296 
behavioural change. The use of a theoretical basis ensured that the research and outputs were 297 
grounded in behavioural theories of change.  298 
 299 
However, there are limitations to the research and the data generated. Despite employing 300 
purposive sampling, a wider range of participants, such as unemployed or less educated 301 
members of the general public, and nurses may have impacted the findings. While it is 302 
possible that data saturation was not achieved, a number of important themes and potential 303 
solutions were identified.  304 
 305 
Interpretation of study findings 306 
This study confirms the usefulness of the TDF and has provided valuable in-depth description 307 
and understanding of a number of behaviours which may lead to medication wastage and in 308 
doing so act as barriers or hindrances to all stakeholders striving to reduce wastage. 309 
Implementation of interventions requires behavioural change and the success of 310 
implementing proposed solutions to reduce medication wastage relies on the scrutiny of 311 
barriers and facilitators of the behavior to be changed. There are multiple theories of 312 
behaviour change and overlapping constructs which present a challenge on which theory 313 
should be adopted in research. The TDF was applied in this research since it includes 314 
constructs from 33 behaviour change theories. Moreover, the TDF was used as it is an 315 
integrative framework that allows for the systematic and comprehensive identification of 316 
barriers to change, supports identification of target behaviors for change and informs 317 
implementation strategies of proposed interventions.12 Overlap in the four key themes in line 318 
with the different TDF domains in this research demonstrates the importance of these four 319 
major components and development of strategies for change should be targeted from the 320 
perspective of each of these components. 321 
 322 
The Maltese (or any) free healthcare system as a possible major barrier to medication wastage 323 
reduction was a recurring sub-theme in this study and thus needs to be further looked into. 324 
There is some evidence (albeit limited) that those patients entitled to free medication are 325 
more likely to receive polypharmacy, traditionally defined as “the concurrent use of five or 326 
more medications”.14 Whilst providing free medication could be viewed as a positive step in 327 
terms of patient equality of care, there is a need to research the impact of no charge on patient 328 
request for and use of prescribed medication. It could be hypothesised that patients receiving 329 
free medication are more prone to wastage. Hence the effects of the free healthcare system 330 
need to be fully explored and recognised to fully inform policy debates.13 Moreover, the 331 
perspectives of participants in this study on disease prevention should also be considered as a 332 
means of saving on limited resources, including HCPs’ time and healthcare expenditures. 333 
Notably, the EU Commission staff working document ‘Investing in Health’ very recently 334 
reported that only approximately three percent of the current health expenditure is earmarked 335 
for public health and prevention programmes amongst Member States.14 336 
 337 
Both from practitioner and patient perspectives, medication shortages was discussed in depth 338 
during the focus groups as a key cause of unnecessary hoarding and stocking by patients and 339 
also recommended to patients at times by HCPs. Medication shortages are a global problem 340 
with all medication classes being affected15,16 and have been described for more than a 341 
decade.17 This issue has also been recognised as causing great distress to patients, their carers 342 
and families.15 There are many and complex reasons for medication shortages including 343 
manufacturing quality problems, the increased demand of medication and changes in 344 
regulatory standards of manufacturing plants, amongst others.18 Following a reflection paper 345 
on the issue of medication shortages by the European Medicines Agency (EMA), the 346 
European Association of Hospital Pharmacists (EAHP)15 issued a number of 347 
recommendations. One key recommendation is the collaborative involvement of patients’ 348 
organisations, using their expertise to issue guidelines for patients and HCPs to promote 349 
rationale medication use. Interestingly focus group participants were in accord with this 350 
recommendation, proposing one solution involving collaboration with patient groups to 351 
provide guidance, support and reassurance. 352 
 353 
Medication non-adherence was discussed at length during the focus groups and was 354 
considered to be one of the key barriers hindering resolution of medication wastage. 355 
Furthermore, medication non-adherence can lead to leftover unused medication in households 356 
which can be later used for an inappropriate indication or may expire and hence pose a public 357 
health issue, including environmental implications through improper disposal. A very recent 358 
review of 51 systematic reviews of the determinants of adherence identified 771 individual 359 
factors for non-adherence to medicines for chronic conditions. These factors were grouped 360 
into eight clusters, two of which were the patients (key issue in the elderly) and the medicine 361 
(key issue with polypharmacy).19 While this research does not focus exclusively on non-362 
adherence, future research should pay attention to these factors could positively impact 363 
medication wastage.  364 
 365 
The lack of awareness and the existence of knowledge gaps in relation to medication wastage 366 
both amongst the public and HCPs emerged in focus group discussions. Future reseach 367 
aiming at the knowledge-behaviour gap through different programs designed to educate 368 
different age groups and different stakeholders was considered as the main goal to reduce 369 
medication wastage. However, this knowledge-behaviour gap cannot be seen as a standalone 370 
barrier in the issue of medication wastage but has to be seen in the context of all the other 371 
factors elicited by participants, such as psychological factors in terms of fear of medication 372 
unavailability. 373 
 374 
Political interference contributing to wastage and as a potential barrier to implementing 375 
wastage reduction strategies was discussed in all groups and by almost all participants. 376 
Undermining of HCPs and scientific experts by political influence has been described 377 
elsewhere.20,21 In a commentary, Rest and Halpern argue that public policy decisions need to 378 
be informed by independent scientists rather than through political interference if one wants 379 
to ensure a good government and a functioning democracy.22 Pham et al. describe the 380 
importance of segregating ‘macro-level decisions’ generated at a political debate level from 381 
‘micro-level decisions’.23 This is in line with participants’ suggestions around the need to 382 
redefine political will.  383 
 384 
A comprehensive description of strategies to potentially reduce wastage was elicited. These 385 
will require intervention at macro-contextual levels, meso-transactional level and at the 386 
micro-organisational level. Recommended interventions and policies to change behaviour 387 
within this study fit well with the ‘Behaviour Change Wheel’, which promotes uptake and 388 
optimal use of strategies.24 Implementation of any of these strategies is likely to be an 389 
iterative process, especially since each and every strategy merits further consideration which 390 
will generate its own multifaceted challenges. Nonetheless, implementation of some 391 
strategies might not be as simple or straightforward as one might think. In a study employing 392 
photo-elicitation to identify different types of wastage, Goff et al. stated that whilst 393 
attempting to reduce medication wastage one needs to be careful so as not to generate other 394 
forms of wastage, such as the time and money invested in implementing a specific 395 
intervention which may not always outweigh the benefits of introducing the intervention.25 396 
 397 
Future research 398 
One of the benefits of this research is the linkage to practice developments. While there are 399 
many future research areas and questions which emerge from this research, there are key 400 
priority areas which need to be targeted: the effect of policy implementation on practice from 401 
the HCP perspective; effects of education on different age groups and stakeholders; and the 402 
overall impact of the interventions discussed within this paper on medication wastage. 403 
 404 
Conclusion 405 
This study has employed a theoretical framework to identify key underlying medication 406 
wastage related behaviours (such as system, practitioner and patient effects) which require 407 
attention as part of strategic development. 408 
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Table 1: HCP demographics 499 
Participant Age Sex Profession Years in 
profession 
Main role Other 
experience 
1 47 F Pharmacist 24 Hospital 
pharmacist 
  
2 23 M Pharmacist 1 Hospital 
pharmacist 
Community 
pharmacist 
3 31 M Pharmacist 8 Community 
pharmacist 
  
4 35 M Pharmacist 12 Hospital 
pharmacist 
Community 
pharmacist 
5 28 M Doctor 5 Hospital doctor   
6 38 M Pharmacist 15 Hospital 
pharmacist 
Medical 
representative 
7 32 M Pharmacist 9 Responsible 
person/regulatory 
affairs pharmacist 
  
8 27 F Doctor 4 Hospital doctor   
9 28 F Pharmacist 5 Hospital 
pharmacist 
Community 
pharmacist 
10 43 F Doctor 20 Hospital doctor   
11 35 M Pharmacist 12 Hospital 
pharmacist 
  
12 32 F Pharmacist 9 Hospital 
pharmacist 
Community 
pharmacist 
13 36 F Pharmacist 13 Hospital 
pharmacist 
Community 
pharmacist 
14 26 M Doctor 4 Hospital doctor   
15 38 F Doctor 17 Hospital doctor   
16 26 M Doctor 4 Hospital doctor   
17 26 F Pharmacist 3 Hospital 
pharmacist 
Community 
pharmacist 
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Table 2: General public demographics 518 
Participant Age Gender Profession Level of education 
1 34 M PhD Nursing Postgraduate 
2 24 M Accountant Postgraduate 
3 36 F Director Postgraduate 
4 32 F Assistant 
director 
Postgraduate 
5 63 F Housewife Primary 
6 56 F Housewife Secondary 
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Table 3: Key themes and sub-themes mapped to TDF domains 535 
Theoretical Domain Key themes (sub-themes) 
Knowledge 1. Practitioner effects (knowledge of the consequences of 
medication wastage on economy, staff resources) 
Skills 1. Practitioner effects (ability of practitioners) 
2. Patient effects (non-adherence to medication by patients)  
Beliefs about capabilities and 
their social/professional role 
and identity 
1. Practitioner effects (HCPs as educators, time constraints. 
overstocking of medication by HCPs) 
2. Political effects (failing system) 
3. Societal effects (social influences - global force) 
Optimism 1. Practitioner effects (psychological influences - stress, 
obsessed, discouraged, optimistic) 
Beliefs about consequences 1. Practitioner effects (consequences of medication 
unavailability to treat their patients) 
2. Patient effects (consequences of medication unavailability for 
patients’ conditions, patients’ unawaress of consequences of 
unused returned medication) 
3. Political effects (financial consequences of inappropriate 
prescribing/dispensing on country and tax payer) 
Reinforcement 1. Practitioner effects (HCP incentive - uphill battle, 
professionalism) 
Intentions 
 
1. Political effects (the free healthcare system, unclear goals 
within the Government health system) 
Environmental context and 
resources 
1. Practitioner effects (lack of patient review, lack of patient 
information, multiple prescribers, lack of patient registration, 
lack of treatment management guidelines) 
2. Patient effects (selfish practices, confrontation, vulnerability) 
3. Political effects (lack of resources, lack of harmonisation) 
4. Societal effects (lack of education amongst certain social 
classes, abuse of free healthcare system) 
Social influences 
 
 
1. Practitioner effects (mentality, communication, power, 
pressure by work colleagues, pharmaceutical lobbying) 
2. Patient effects (pressure of HCPs by patients to prescribe or 
dispense) 
Emotion 1. Practitioner and patient effects (fear of medication 
unavailability) 
Behavioural regulation 1. Practitioner effects (correct prescribing and accountability, 
medication use reviews, improved documentation, improved 
communication) 
2. Patients effects (increase patient reassurance, patient 
empowerment) 
3. Political effects (reduce political interference, stock 
management, budgeting, independent body governing free 
healthcare system, pharmaceutical identity card, 
infrastructure, incentives, medication fee, reimbursement, 
compulsory private insurance, medication take-back scheme 
with cash card, high consumption medications, disease 
prevention) 
4. Societal effects (increase awareness, strategies and settings to 
deliver education) 
Goals 1. Practitioner effects, patients effects, political effects and 
societal effects (need for education of all stakeholders 
including HCPs and patients) 
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